Joanne Derdak

Also affiliated with Center for Cancer Research

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy”.

Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy

Cancer Cell(2023)10.1016/j.ccell.2023.11.011

N/A

2.4DataRank · unranked

110 citations

Tara Murty, Ahmad Alimadadi, Cristina F. Contreras, Caroline Duault, Priyanka B. Subrahmanyam +39 more

Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas

Neuro-Oncology(2023)10.1093/neuonc/noad086

N/A

2.3DataRank · unranked

97 citations

Eva Dombi, Pamela L. Wolters, Andrea Baldwin, Anne Dufek, Kailey R. Herrera +14 more

Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity

Neuro-Oncology(2022)10.1093/neuonc/noac109

N/A

1.7DataRank · unranked

66 citations

Brittany Glassberg, Pamela L. Wolters, Eva Dombi, Andrea Baldwin, Michael J. Fisher +18 more

Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0709

N/A

0.652DataRank · unranked

20 citations

R. Taylor Sundby, Donna Bernstein, John Glod, Rosandra N. Kaplan, Marielle E. Yohe +17 more

Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3612

N/A

0.483DataRank · unranked

24 citations

Andrea M. Gross, Eva Dombi, Cecilia Tibery, Amanda Carbonell, Naoko Takebe +13 more

Disease detection methodologies in relapsed B‐cell acute lymphoblastic leukemia: Opportunities for improvement

Pediatric Blood & Cancer(2020)10.1002/pbc.28149

N/A

0.406DataRank · unranked

14 citations

Constance M. Yuan, Amita Kulshreshtha, Alina Dulau‐Florea, Dalia Salem, Gaurav K. Gupta +12 more

Results of a phase I trial of ganitumab plus dasatinib in patients with rhabdomyosarcoma (RMS).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.11561

N/A

0DataRank · unranked

4 citations

Donna Bernstein, John Glod, Rosandra N. Kaplan, John Shern, Marielle E. Yohe +14 more

Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I–Related Plexiform Neurofibromas

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1696

N/A

0DataRank · unranked

30 citations

John Glod, Melissa Spencer, Miki Kasai, Joanne Derdak, Eva Dombi +9 more

The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas

Neuro-Oncology Advances(2020)10.1093/noajnl/vdaa095

N/A

0DataRank · unranked

38 citations

Eva H. Baker, Andrea M. Gross, Patricia Whitcomb, Andrea Baldwin, Joanne Derdak +9 more